Tulobuterol Patch in Pediatric Patients Undergoing Tonsillectomy

NACompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Tonsillar Hypertrophy
Interventions
DRUG

Tulobuterol Hydrochloride

The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.

DRUG

Placebo transdermal patch

The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.

Trial Locations (4)

03080

Seoul National University Hospital, Seoul

03721

Hyun-Joo Kim, Seoul

06351

Jin-Kyung Kim, Seoul

06973

Chung-Ang University Hospital, Seoul

All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

collaborator

Severance Hospital

OTHER

lead

Seoul National University Hospital

OTHER

NCT04057469 - Tulobuterol Patch in Pediatric Patients Undergoing Tonsillectomy | Biotech Hunter | Biotech Hunter